We have observed
11 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 21, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CYCLIC APELIN ANALOGS
ANTIBODIES FOR IL-17C
NOVEL METHODS FOR DISPLAYING CYCLIC PEPTIDES ON BACTERIOPHAGE PARTICLES
CYCLIC GALANIN-ANALOGS AND USES THEREOF
COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF
COMBINATIONS AND USES THEREOF
ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS
ANTAGONISTS OF IL-17C FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS
METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
ANTI-CD19 ANTIBODY FORMULATIONS